-
Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study
•
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its investigational therapy, NR-20201. This allogeneic adipose-derived mesenchymal stem cell therapy is in development for the treatment of acute ischemic stroke. Preclinical study results…
-
CR Sanjiu to Acquire Significant Stake in Tasly Pharmaceuticals in a Deal Valued at $870 Million
•
China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999), has announced its intention to conditionally purchase a substantial 28% stake in fellow Chinese firm Tasly Pharmaceuticals (SHA: 600535). The transaction involves the acquisition of 418,306,002 shares, with a proposed consideration of RMB 14.85 per share, culminating in a total deal value…
-
Tasly Pharmaceuticals Gets NMPA Go-Ahead for Clinical Trial of Stem Cell Therapy in Heart Failure
•
Tasly Pharmaceuticals (SHA: 600535), a leading pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its human umbilical cord mesenchymal stem cell injection, B2278. The study aims to evaluate the efficacy of this therapy…
-
Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH
•
Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its human fibroblast growth factor 21 injection, B1344, in patients with non-alcoholic steatohepatitis (NASH). This development marks a significant step in the…
